Hendershot Investments Inc. Sells 25 Shares of Becton, Dickinson and Company (NYSE:BDX)

Hendershot Investments Inc. cut its position in Becton, Dickinson and Company (NYSE:BDX) by 0.2% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 16,608 shares of the medical instruments supplier’s stock after selling 25 shares during the period. Hendershot Investments Inc.’s holdings in Becton, Dickinson and were worth $3,240,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Cohen Lawrence B boosted its stake in Becton, Dickinson and by 39.1% in the first quarter. Cohen Lawrence B now owns 4,272 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 1,200 shares during the period. Rockland Trust Co. bought a new position in Becton, Dickinson and during the first quarter worth approximately $307,000. Wells Fargo & Company MN raised its position in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares in the last quarter. AMG National Trust Bank raised its position in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock worth $1,813,000 after buying an additional 401 shares in the last quarter. Finally, Integrated Wealth Management raised its position in Becton, Dickinson and by 3.4% in the first quarter. Integrated Wealth Management now owns 5,444 shares of the medical instruments supplier’s stock valued at $999,000 after buying an additional 181 shares during the period. 75.57% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE:BDX) traded down 0.81% during midday trading on Friday, hitting $197.69. 989,225 shares of the company traded hands. The stock’s 50-day moving average is $199.60 and its 200-day moving average is $188.53. The firm has a market capitalization of $44.99 billion, a PE ratio of 57.25 and a beta of 1.05. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. The firm’s revenue was down 5.1% on a year-over-year basis. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.48%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by BNB Daily and is owned by of BNB Daily. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/hendershot-investments-inc-sells-25-shares-of-becton-dickinson-and-company-nysebdx-updated-updated-updated.html.

A number of equities analysts recently commented on BDX shares. Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $186.00 to $200.00 in a research note on Monday, April 24th. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Cowen and Company reaffirmed an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Finally, BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $195.79.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. Insiders have sold 57,631 shares of company stock valued at $11,112,178 in the last 90 days. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply